Orthocell confirms Australian reimbursement for CelGro

Regenerative medicine company Orthocell (ASX:OCC) has announced it has received notification from the Australian Department of Health that its CelGro Dental has been included on the Prostheses List (PL).

Inclusion on the PL means CelGro Dental will be reimbursed by private health insurers for approved dental bone and soft tissue repair procedures.

Managing director Paul Anderson said, “Inclusion of CelGro Dental on the Prostheses List is the culmination of translational research and a regulatory program to bring this product to the Australian market. I am delighted that patients now have access to a premium dental membrane product designed, manufactured and reimbursed in Australia.”

The company said the reimbursement will assist its negotiations with multi-national dental companies and national dealers for marketing and distribution rights. Orthocell said it will manufacture the finished product.

/Public Release. This material comes from the originating organization and may be of a point-in-time nature, edited for clarity, style and length. View in full here.